HK1255046A1 - 粒細胞巨噬細胞集落刺激因子的拮抗劑的用途 - Google Patents

粒細胞巨噬細胞集落刺激因子的拮抗劑的用途

Info

Publication number: HK1255046A1
Authority: HK; Hong Kong
Prior art keywords: antagonist; stimulating factor; macrophage colony; granulocyte macrophage; granulocyte
Prior art date: 2008-12-22

Application number

HK18114170.3A

Other languages

English (en)

Chinese (zh)

Inventor

約翰‧艾倫‧漢密爾頓

安德魯‧大衛‧庫克

Original Assignee

墨爾本大學

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-22

Filing date

2018-11-07

Publication date

2019-08-02

2018-11-07 Application filed by 墨爾本大學 filed Critical 墨爾本大學

2019-08-02 Publication of HK1255046A1 publication Critical patent/HK1255046A1/zh

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

HK18114170.3A 2008-12-22 2018-11-07 粒細胞巨噬細胞集落刺激因子的拮抗劑的用途 HK1255046A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13968708P	2008-12-22	2008-12-22
US16449109P	2009-03-30	2009-03-30

Publications (1)

Publication Number	Publication Date
HK1255046A1 true HK1255046A1 (zh)	2019-08-02

Family

ID=42286785

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK18114170.3A HK1255046A1 (zh)	2008-12-22	2018-11-07	粒細胞巨噬細胞集落刺激因子的拮抗劑的用途
HK18114356.9A HK1255227A1 (zh)	2008-12-22	2018-11-09	疼痛治療

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HK18114356.9A HK1255227A1 (zh)	2008-12-22	2018-11-09	疼痛治療

Country Status (12)

Country	Link
US (3)	US8475796B2 (ru)
EP (2)	EP2387418B1 (ru)
JP (3)	JP5674677B2 (ru)
KR (1)	KR101761324B1 (ru)
CN (2)	CN108014335A (ru)
AU (2)	AU2009329811B2 (ru)
BR (1)	BRPI0918103A2 (ru)
CA (1)	CA2747206C (ru)
ES (1)	ES2685895T3 (ru)
HK (2)	HK1255046A1 (ru)
RU (2)	RU2630969C2 (ru)
WO (1)	WO2010071923A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2685895T3 (es) *	2008-12-22	2018-10-15	The University Of Melbourne	Tratamiento del dolor
HUE028615T2 (en)	2008-12-22	2016-12-28	Univ Melbourne	Treatment of osteoarthritis
KR20210021153A (ko) *	2012-09-20	2021-02-24	모르포시스 아게	류마티스 관절염에 대한 치료
EP3916013A1 (en) *	2012-09-20	2021-12-01	MorphoSys AG	Treatment for rheumatoid arthritis with anti-gm-csf antibody
JP6339578B2 (ja) *	2012-10-31	2018-06-06	タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａＧｍｂＨ	Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es)	2012-10-31	2015-05-27	Amgen Res (Munich) Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US20160024200A1 (en) *	2013-03-14	2016-01-28	John Schrader	Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
US10745475B2 (en)	2013-08-30	2020-08-18	Takeda Gmbh	Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
NZ750976A (en)	2016-09-19	2023-01-27	I Mab Biopharma Hangzhou Co Ltd	Anti-gm-csf antibodies and uses thereof
CN107840885B (zh) *	2016-09-19	2020-11-10	天境生物科技(上海)有限公司	Gm-csf抗体及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY105946A (en) *	1989-07-14	1995-02-28	Schering Corp	Antagonists of gm-csf derived from the carboxyl terminus.
SG59954A1 (en)	1989-08-11	1999-02-22	Amrad Corp Ltd	Improvements in granulocyte-macrophage colony- stimulating factor receptor and derivatives thereof
WO1994009149A1 (en)	1990-08-10	1994-04-28	Amrad Corporation Limited	Monoclonal antibody
WO1994011404A1 (en) *	1992-11-19	1994-05-26	Dana-Farber Cancer Institute	Antibodies for gm-csf receptor and uses thereof
PT859841E (pt)	1995-08-18	2002-11-29	Morphosys Ag	Bibliotecas de proteinas/ (poli) peptidos
AUPP525198A0 (en)	1998-08-13	1998-09-03	Medvet Science Pty. Ltd.	Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en)	2000-03-20	2006-09-19	Warner-Lambert Company Llc	Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en)	2000-05-08	2008-11-25	The University Of Melbourne	Method of treatment and agents useful for same
SE0102067D0 (sv) *	2001-06-11	2001-06-11	A & Science Invest Ab	Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
US20060067938A1 (en)	2001-10-26	2006-03-30	Sherif Daouti	Methods for the treatment of osteoarthritis and compositions thereof
US7714113B2 (en)	2002-02-13	2010-05-11	Ludwig Institute For Cancer Research	Fusion proteins of humanized g250 specific antibodies and uses thereof
AU2002950957A0 (en) *	2002-08-23	2002-09-12	The Walter And Eliza Hall Institute Of Medical Research	A method of treatment and prophylaxis
US7569364B2 (en)	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
US20040241755A1 (en)	2003-06-02	2004-12-02	Pfizer Inc.	Human cell assay to determine effect of sample compounds on Col2 enhancer expression
EP1759710B1 (en)	2004-03-31	2014-05-07	Kazuwa Nakao	Remedy or preventive for arthritis
DE602004021773D1 (de)	2004-05-05	2009-08-13	Micromet Ag	Herstellung eines einkettigen fv Antikörperfragments
ES2545769T3 (es)	2005-04-18	2015-09-15	Amgen Research (Munich) Gmbh	Anticuerpos neutralizantes del factor estimulante de colonias de granulocitos y macrófagos humano
HRP20220755T3 (hr) *	2005-05-18	2022-09-02	Morphosys Ag	Anti-gm-csf antitijela i njihova uporaba
JP4736037B2 (ja)	2005-10-26	2011-07-27	株式会社イーベック	ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2629850A1 (en)	2005-12-01	2007-06-07	Domantis Limited	Competitive domain antibody formats that bind interleukin 1 receptor type 1
CA2641169C (en)	2006-02-08	2017-05-02	Morphotek, Inc.	Antigenic gm-csf peptides and antibodies to gm-csf
ES2424467T3 (es)	2006-03-27	2013-10-02	Medimmune Limited	Miembro de unión para el receptor GM-CSF
US7741273B2 (en) *	2006-04-13	2010-06-22	Warsaw Orthopedic, Inc.	Drug depot implant designs
EP2402013A1 (en) *	2006-11-21	2012-01-04	Kalobios Pharmaceuticals, Inc.	Methods of Treating Chronic Inflammatory Diseases using a GM-CSF Antagonist
US7879856B2 (en)	2006-12-22	2011-02-01	Rigel Pharmaceuticals, Inc.	Diaminothiazoles useful as Axl inhibitors
EP2160407A4 (en)	2007-05-23	2011-07-27	Crc For Asthma And Airways Ltd	NEUTRALIZING ANTIBODIES
TW200918553A (en)	2007-09-18	2009-05-01	Amgen Inc	Human GM-CSF antigen binding proteins
US20100297135A1 (en)	2007-11-12	2010-11-25	Crc For Asthma And Airways Ltd.	Epitope for neutralizing antibodies
EP2215119B1 (en)	2007-11-13	2012-12-26	Evec Inc.	Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
JP5688363B2 (ja)	2008-04-28	2015-03-25	カロバイオスファーマシューティカルズインコーポレイティッド	顆粒球−マクロファージコロニー刺激因子に対する抗体
HUE028615T2 (en)	2008-12-22	2016-12-28	Univ Melbourne	Treatment of osteoarthritis
ES2685895T3 (es) *	2008-12-22	2018-10-15	The University Of Melbourne	Tratamiento del dolor
CN102459340A (zh)	2009-04-23	2012-05-16	特罗科隆科学有限公司	粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体

2009
- 2009-12-21 ES ES09833923.7T patent/ES2685895T3/es active Active
- 2009-12-21 US US13/140,839 patent/US8475796B2/en active Active
- 2009-12-21 CN CN201711112956.0A patent/CN108014335A/zh active Pending
- 2009-12-21 JP JP2011541029A patent/JP5674677B2/ja active Active
- 2009-12-21 BR BRPI0918103A patent/BRPI0918103A2/pt not_active Application Discontinuation
- 2009-12-21 CA CA2747206A patent/CA2747206C/en active Active
- 2009-12-21 RU RU2011127333A patent/RU2630969C2/ru active
- 2009-12-21 RU RU2016102346A patent/RU2712166C2/ru active
- 2009-12-21 WO PCT/AU2009/001671 patent/WO2010071923A1/en active Application Filing
- 2009-12-21 KR KR1020117017019A patent/KR101761324B1/ko active IP Right Grant
- 2009-12-21 EP EP09833923.7A patent/EP2387418B1/en active Active
- 2009-12-21 CN CN200980151639.7A patent/CN102256621B/zh active Active
- 2009-12-21 EP EP18170226.7A patent/EP3381471B1/en active Active
- 2009-12-21 AU AU2009329811A patent/AU2009329811B2/en active Active
2013
- 2013-05-28 US US13/903,009 patent/US9352034B2/en active Active
2014
- 2014-07-04 JP JP2014138170A patent/JP6147704B2/ja active Active
2016
- 2016-01-18 AU AU2016200267A patent/AU2016200267B2/en active Active
- 2016-04-29 US US15/142,746 patent/US9834599B2/en active Active
2017
- 2017-04-05 JP JP2017074868A patent/JP2017149740A/ja active Pending
2018
- 2018-11-07 HK HK18114170.3A patent/HK1255046A1/zh unknown
- 2018-11-09 HK HK18114356.9A patent/HK1255227A1/zh unknown

Also Published As

Publication number	Publication date
US20160311896A1 (en)	2016-10-27
CA2747206A1 (en)	2010-07-01
CN102256621B (zh)	2017-12-12
AU2009329811B2 (en)	2016-02-25
US8475796B2 (en)	2013-07-02
RU2016102346A3 (ru)	2019-07-29
EP2387418A4 (en)	2013-07-17
ES2685895T3 (es)	2018-10-15
RU2011127333A (ru)	2013-01-27
JP6147704B2 (ja)	2017-06-14
WO2010071923A1 (en)	2010-07-01
CN102256621A (zh)	2011-11-23
US20110287027A1 (en)	2011-11-24
AU2009329811A1 (en)	2010-07-01
EP2387418B1 (en)	2018-06-13
EP3381471C0 (en)	2024-03-20
AU2016200267A1 (en)	2016-02-11
KR20110117659A (ko)	2011-10-27
JP2012512814A (ja)	2012-06-07
EP3381471B1 (en)	2024-03-20
RU2016102346A (ru)	2018-11-20
JP2017149740A (ja)	2017-08-31
BRPI0918103A2 (pt)	2016-07-05
JP5674677B2 (ja)	2015-02-25
EP3381471A1 (en)	2018-10-03
RU2712166C2 (ru)	2020-01-24
JP2014224123A (ja)	2014-12-04
US9834599B2 (en)	2017-12-05
HK1255227A1 (zh)	2019-08-09
US9352034B2 (en)	2016-05-31
CA2747206C (en)	2018-04-24
AU2016200267B2 (en)	2017-09-07
KR101761324B1 (ko)	2017-07-25
EP2387418A1 (en)	2011-11-23
RU2630969C2 (ru)	2017-09-15
CN108014335A (zh)	2018-05-11
US20130243791A1 (en)	2013-09-19

Publication	Publication Date	Title
HK1255046A1 (zh)	2019-08-02	粒細胞巨噬細胞集落刺激因子的拮抗劑的用途
HK1163770A1 (en)	2012-09-14	Adjustable ladders
IL219390A0 (en)	2012-06-28	Il-17a antagonists
PT2513058T (pt)	2017-01-26	Métodos de síntese de inibidores do fator xa
IL210207A0 (en)	2011-03-31	Compounds having antiviral properties
PL2328545T3 (pl)	2016-04-29	Zastosowanie glukozyloglicerolu
AU327287S (en)	2009-08-24	Table skirting panel
ZA201008076B (en)	2012-07-25	Calibration of dtonators
ZA201105056B (en)	2012-12-27	4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
HK1160925A1 (zh)	2012-08-17	組織蛋白酶的用途
GB0916609D0 (en)	2009-11-04	Coated insulation board
EP2328873A4 (en)	2011-09-07	PREPARATION OF RANOLAZINE
BRPI1006514A2 (pt)	2019-01-08	antagonista do gm-csf
EP2391895A4 (en)	2014-11-05	PRECISION MEASUREMENT OF WAVEFORMS
PL2237782T3 (pl)	2018-12-31	Zastosowanie tetrahydropirymidyn
EP2370476A4 (en)	2012-07-11	IONIC COMONOMER SYNTHESIS SOLUBLE IN STYRENE
PL388186A1 (pl)	2010-12-06	Listwa przypodłogowa
EP2257303A4 (en)	2012-08-01	USES OF MODIFIED ELR-CXC G31P CHEMOKINE
PL2358570T3 (pl)	2015-03-31	Izolacja akustyczna
EP2369920A4 (en)	2012-07-11	IONIC COMONOMER SYNTHESIS SOLUBLE IN STYRENE
TWM371466U (en)	2010-01-01	Hidden-type extension table
GB0715133D0 (en)	2007-09-12	Granulocyte colony stimulating factor
GB0724013D0 (en)	2008-01-23	Granulocyte colony stimulating factor
PL384708A1 (pl)	2009-09-28	Stół pomiarowy
PL118323U1 (pl)	2011-01-03	Listwa przypodłogowa